Finch Therapeutics Group, Inc. reported unaudited consolidated impairment of long-lived assets for the first quarter ended March 31, 2023. Impairment of long-lived assets was $13,141,000. The increase in net loss was primarily due to a charge of $32.9 million for the full impairment of the Company's in-process research and development (IPR&D) asset.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.03 USD | -4.25% | -18.47% | -43.77% |
25/03 | Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
12/03 | Top Premarket Decliners | MT |
1st Jan change | Capi. | |
---|---|---|
-43.77% | 3.4M | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- FNCH Stock
- News Finch Therapeutics Group, Inc.
- Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023